Tislelizumab Plus Chemotherapy Conversion Therapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Summary
A single-arm, single-center, open-label observational clinical study (NCT07549100) registered on ClinicalTrials.gov will enroll 30 patients with initially unresectable locally advanced esophageal squamous cell carcinoma (ESCC) to receive tislelizumab (200 mg, day 2, Q3W) combined with albumin-bound paclitaxel (260 mg/m², day 1, Q3W) plus cisplatin (75 mg/m²) or carboplatin (AUC=5) for 2–4 cycles. The primary endpoint is the conversion rate to surgery following multidisciplinary team (MDT) reassessment of tumor staging; secondary endpoints include pathological complete response (pCR), objective response rate (ORR), and safety. The study was posted on April 23, 2026.
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This ClinicalTrials.gov registry entry describes a newly registered observational study (NCT07549100) evaluating tislelizumab in combination with albumin-bound paclitaxel and platinum-based chemotherapy as conversion therapy for patients with initially unresectable locally advanced esophageal squamous cell carcinoma. The study will enroll 30 patients at a single center; participants will undergo 2–4 treatment cycles before tumor reassessment by a multidisciplinary team to determine surgical resectability. No regulatory obligations are imposed by this registry entry.
For sponsors, clinical investigators, and oncology research programs, this trial represents a newly registered dose-finding/feasibility study in a high unmet-need population. The conversion-therapy design (using immunotherapy plus chemotherapy to render tumors operable) is consistent with an emerging standard-of-care pathway in locally advanced esophageal cancer. Research coordinators should note the specific inclusion criteria, dosing schedule (Q3W cycles), and endpoints when assessing patient eligibility or competitive enrollment landscape.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
Observational NCT07549100 Kind: OBSERVATIONAL Apr 23, 2026
Abstract
This is a single-arm, single-center, open-label, observational clinical study. A total of 30 patients with initially unresectable locally advanced esophageal squamous cell carcinoma will be enrolled.Eligible patients will receive albumin-bound paclitaxel (260 mg/m², day 1, every 3 weeks [Q3W]) plus cisplatin (75 mg/m²) or carboplatin (AUC = 5), in combination with tislelizumab (200 mg, day 2, Q3W), for 2-4 cycles. Tumor staging will be reassessed thereafter, and the feasibility of surgical resection will be determined based on multidisciplinary team (MDT) discussion.The primary endpoint is the conversion rate to surgery.
Secondary endpoints include pathological complete response (pCR), objective response rate (ORR), and safety.
Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma
Interventions: Tislelizumab Plus Chemotherapy
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.